argenx SE
XBRU:ARGX

Watchlist Manager
argenx SE Logo
argenx SE
XBRU:ARGX
Watchlist
Price: 782.6 EUR 1.5%
Market Cap: 48.2B EUR
Section:
 

Relative Value

The Relative Value of one ARGX stock under the Base Case scenario is 929.47 EUR. Compared to the current market price of 782.6 EUR, argenx SE is Undervalued by 16%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ARGX Relative Value
Base Case
929.47 EUR
Undervaluation 16%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

15.5
P/S
P/S
Price to Sales
15.5
vs History
7
vs Industry
34
Median 3Y
0
Median 5Y
0
Industry
7.9
Forward
13
More Details
36.4
P/E
P/E
Price to Earnings
36.4
vs History
6
vs Industry
4
Median 3Y
0
Median 5Y
0
Industry
24
Forward
50.3
More Details
137.6
P/OCF
P/OCF
Price to OCF
137.6
vs History
0
vs Industry
Median 3Y
0
Median 5Y
0
Industry
21.6
More Details
183.8
P/FCFE
P/FCFE
Price to FCFE
183.8
vs History
0
vs Industry
Median 3Y
0
Median 5Y
0
Industry
23.7
More Details
9.1
P/B
P/B
Price to Book Value
9.1
vs History
6
vs Industry
11
Median 3Y
7.3
Median 5Y
5.6
Industry
3.4
More Details
14.4
EV/S
EV/S
Enterprise Value to Sales
14.4
vs History
7
vs Industry
30
Median 3Y
0
Median 5Y
0
Industry
8.3
Forward
12.1
More Details
16
EV/GP
EV/GP
Enterprise Value to Gross Profit
16
vs History
14
vs Industry
29
Median 3Y
0
Median 5Y
0
Industry
10.3
More Details
63
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
63
vs History
19
vs Industry
0
Median 3Y
0
Median 5Y
0
Industry
6.7
Forward
41.7
More Details
64.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
64.8
vs History
9
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.2
Forward
44.9
More Details
128.4
EV/OCF
EV/OCF
Enterprise Value to OCF
128.4
vs History
0
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.2
More Details
168
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
168
vs History
0
vs Industry
Median 3Y
0
Median 5Y
0
Industry
6.7
More Details
19.1
EV/IC
EV/IC
Enterprise Value to IC
19.1
vs History
7
vs Industry
10
Median 3Y
9.6
Median 5Y
5.4
Industry
5.7
More Details

Multiples Across Competitors

ARGX Competitors Multiples
argenx SE Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NL
argenx SE
XBRU:ARGX
47.9B EUR 15.5 36.4 63 64.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 071 784.8 -161 938.1 -196 644.6 -194 400.6
US
Abbvie Inc
NYSE:ABBV
399.6B USD 6.7 170.2 16.5 23.4
US
Amgen Inc
NASDAQ:AMGN
177.5B USD 4.9 25.3 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
150.6B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.7B USD 9.9 31.5 23.1 24.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 067.7 -527.6 -574.5 -559.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
75.6B USD 5.3 16.5 15.7 17.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
60.4B USD 18.8 1 385.9 182.8 221.7
AU
CSL Ltd
ASX:CSL
89.9B AUD 3.8 19.9 13.3 16.6
US
Seagen Inc
F:SGT
39.3B EUR 19.9 -61.1 -65.8 -59.4
P/S Multiple
Revenue Growth P/S to Growth
NL
argenx SE
XBRU:ARGX
Average P/S: 3 097 631.1
15.5
49%
0.3
FR
Pharnext SCA
OTC:PNEXF
34 071 784.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 067.7
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.3
6%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
18.8
46%
0.4
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
US
S
Seagen Inc
F:SGT
19.9
30%
0.7
P/E Multiple
Earnings Growth PEG
NL
argenx SE
XBRU:ARGX
Average P/E: 213
36.4
40%
0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 938.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
170.2
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.3
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
9%
1.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 385.9
N/A N/A
AU
CSL Ltd
ASX:CSL
19.9
11%
1.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.1 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NL
argenx SE
XBRU:ARGX
Average EV/EBITDA: 43.1
63
807%
0.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 644.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.7
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
182.8
N/A N/A
AU
CSL Ltd
ASX:CSL
13.3
8%
1.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.8 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NL
argenx SE
XBRU:ARGX
Average EV/EBIT: 49.9
64.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 400.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
13%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
221.7
N/A N/A
AU
CSL Ltd
ASX:CSL
16.6
11%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.4 N/A N/A

See Also

Summary
ARGX intrinsic value, competitors valuation, and company profile.
DCF Valuation
ARGX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ARGX stock valuation using valuation multiples.
Wall Street Estimates
ARGX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ARGX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 301,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.